Palvella's topical QTORIN rapamycin reduces bleeding in cutaneous venous malformations

Palvella Therapeutics (NASDAQ:PVLA) reported positive clinical data from its Phase 2 TOIVA trial evaluating its proprietary topical formulation of rapamycin, detailing significant therapeutic benefits for patients suffering from rare vascular skin disorders.

The Wayne, Pennsylvania-based biopharmaceutical company presented the clinical update during an oral session at the 83rd Annual Meeting of the Society for Investigative Dermatology (SID) in Atlanta, Georgia.

The data focused on the efficacy of QTORIN™ 3.9% rapamycin gel in patients diagnosed with cutaneous venous malformations (VMs), a debilitating genetic condition characterized by chronically dilated, painful, and prone-to-bleeding vascular lesions.

Among the high-risk patient cohort presenting with baseline bleeding at the start of the study, treatment with the topical gel led to a statistically significant improvement of 2.5 points on the cVM-IGA Bleeding scale (p=0.003) by the end of the evaluation window.

Furthermore, the clinical validation was matched by patient-reported outcomes, with 100% of the bleeding cohort reporting they were either "satisfied" or "very satisfied" with the therapeutic intervention at Week 12.

The clinical presentation also introduced data from baseline qualitative interviews, which underscored the profound disease burden carried by individuals living with the condition.

Participants reported substantial physical pain, functional limitations in daily activities, and an extreme psychosocial burden linked to the highly visible and unpredictable nature of the lesions.

There are currently no localized or systemic therapies approved by the U.S. Food and Drug Administration (FDA) specifically indicated for this condition.

Cutaneous venous malformations affect an estimated 75,000 to 100,000 individuals in the United States alone.

Management indicated that the positive Phase 2 TOIVA results validate the QTORIN platform's ability to deliver therapeutic drug concentrations directly into the basal layers of the epidermis while minimizing systemic absorption.

Palvella plans to utilize these data to finalize its Phase 3 registrational trial design with regulatory authorities, positioning QTORIN rapamycin to potentially become the first FDA-approved therapeutic option for this underserved orphan patient population.